NASDAQ:NEOG - Neogen Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $81.50
  • Forecasted Upside: 1.85 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$80.02
▼ -1.49 (-1.83%)
1 month | 3 months | 12 months
Get New Neogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEOG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEOG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$81.50
▲ +1.85% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Neogen in the last 3 months. The average price target is $81.50, with a high forecast of $88.00 and a low forecast of $75.00. The average price target represents a 1.85% upside from the last price of $80.02.
Hold
The current consensus among 3 polled investment analysts is to hold stock in Neogen. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/9/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/8/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/23/2020Roth CapitalBoost Price TargetNeutral$67.00 ➝ $75.00Medium
i
7/21/2020William BlairReiterated RatingMarket PerformLow
i
Rating by J. Kreger at William Blair
7/14/2020StephensReiterated RatingBuy$88.00High
i
Rating by Mark Connelly at Stephens
2/10/2020StephensInitiated CoverageEqual Weight ➝ Overweight$88.00High
i
12/31/2019Roth CapitalReiterated RatingNeutralMedium
i
Rating by G. Sweeney at Roth Capital
7/24/2019Craig HallumBoost Price TargetBuy ➝ In-Line$72.00 ➝ $78.00High
i
5/23/2019GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
i
3/19/2019Craig HallumUpgradeHold ➝ Buy$62.76Medium
i
12/21/2018Craig HallumReiterated RatingHold$60.00High
i
12/14/2018Roth CapitalReiterated RatingNeutralLow
i
Rating by G. Sweeney at Roth Capital
7/18/2018Craig HallumBoost Price TargetHold$65.00 ➝ $70.00Medium
i
3/26/2018StephensReiterated RatingEqual Weight ➝ Hold$62.00 ➝ $65.00Medium
i
1/10/2018StephensReiterated RatingHold$62.00Low
i
1/4/2018Roth CapitalSet Price TargetHold$82.00 ➝ $62.00Medium
i
Rating by Gerry Sweeney at Roth Capital
12/7/2017Craig HallumBoost Price TargetHold$46.50 ➝ $60.00Low
i
12/5/2017Roth CapitalInitiated CoverageNeutral ➝ Neutral$61.50Medium
i
Rating by G. Sweeney at Roth Capital
7/14/2017CL KingInitiated CoverageNeutral ➝ NeutralLow
i
8/29/2016Craig HallumDowngradeBuy ➝ HoldN/A
i
Rating by C. Haff at Craig Hallum
8/9/2016Craig HallumUpgradeHold ➝ BuyN/A
i
Rating by C. Haff at Craig Hallum
3/25/2016Janney Montgomery ScottLower Price TargetNeutral$39.00N/A
i
3/25/2016Craig HallumLower Price TargetHold$48.75 ➝ $36.75N/A
i
Rating by Charles Haff at Craig Hallum
3/24/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by Anton Brenner at Roth Capital
(Data available from 3/3/2016 forward)
Neogen logo
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Read More

Today's Range

Now: $80.02
$80.02
$81.84

50 Day Range

MA: $84.41
$80.87
$88.48

52 Week Range

Now: $80.02
$48.91
$89.32

Volume

553 shs

Average Volume

214,853 shs

Market Capitalization

$4.26 billion

P/E Ratio

70.19

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Neogen?

The following Wall Street research analysts have issued research reports on Neogen in the last twelve months: Roth Capital, Stephens, TheStreet, and William Blair.
View the latest analyst ratings for NEOG.

What is the current price target for Neogen?

2 Wall Street analysts have set twelve-month price targets for Neogen in the last year. Their average twelve-month price target is $81.50, suggesting a possible upside of 1.8%. Stephens has the highest price target set, predicting NEOG will reach $88.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $75.00 for Neogen in the next year.
View the latest price targets for NEOG.

What is the current consensus analyst rating for Neogen?

Neogen currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NEOG, but not buy more shares or sell existing shares.
View the latest ratings for NEOG.

What other companies compete with Neogen?

How do I contact Neogen's investor relations team?

Neogen's physical mailing address is 620 LESHER PLACE, LANSING MI, 48912. The company's listed phone number is 517-372-9200 and its investor relations email address is [email protected] The official website for Neogen is www.neogen.com.